NasdaqCM - Delayed Quote USD

Artelo Biosciences, Inc. (ARTL)

1.0500
+0.0400
+(3.96%)
At close: May 30 at 4:00:00 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for ARTL

Recent News: ARTL

View More
Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results

Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results
GlobeNewswire 19 days ago
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12’s Effectiveness in Treating Psoriasis

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12’s Effectiveness in Treating Psoriasis
GlobeNewswire last month
Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025

Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025
GlobeNewswire 2 months ago
Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results

Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results
GlobeNewswire 2 months ago
Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex®

Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex®
GlobeNewswire 3 months ago
Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland

Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland
GlobeNewswire 3 months ago
Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12

Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12
GlobeNewswire 4 months ago
Artelo presents Phase 1 data with ART27.13 in cancer-related anorexia

Artelo presents Phase 1 data with ART27.13 in cancer-related anorexia
TipRanks 5 months ago
Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia

Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia
GlobeNewswire 5 months ago
Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit

Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit
GlobeNewswire 6 months ago
Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium

Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium
GlobeNewswire 6 months ago
View More

Related Tickers

THAR Tharimmune, Inc.
1.4522
-1.21%
 
SLRX Salarius Pharmaceuticals, Inc.
0.7629
-3.43%
 
LYEL Lyell Immunopharma, Inc.
0.4367
+8.74%
 
BXRXQ Baudax Bio, Inc.
0.0001
+9,900.00%
 
AZTR Azitra, Inc.
0.2740
+1.11%
 
ENTO Entero Therapeutics, Inc.
0.4335
+5.22%
 
CMMB Chemomab Therapeutics Ltd.
1.3200
-3.65%
 
SNPX Synaptogenix, Inc.
2.5150
+2.24%
 
DYAI Dyadic International, Inc.
1.0370
+0.19%
 
HOOK HOOKIPA Pharma Inc.
1.5900
-1.24%